Wealth Enhancement Advisory Services
CGTX icon

Wealth Enhancement Advisory Services’s Cognition Therapeutics CGTX Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,000
Closed -$14.1K – 3631
2025
Q4 		$14.1K Sell
10,000
-1,000
-9% -$1.62K ﹤0.01% 3614
2025
Q3 		$19.3K Buy
11,000
+1,000
+10% +$1.36K ﹤0.01% 3514
2025
Q2 		$4.05K Hold
10,000
– – ﹤0.01% 3375
2025
Q1 		$4.21K Hold
10,000
– – ﹤0.01% 2968
2024
Q4 		$7.01K Buy
+10,000
New +$4.94K ﹤0.01% 2936

Other funds holding CGTX

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return

Wealth Enhancement Advisory Services's CGTX Position: Q1 2026 in Review

Wealth Enhancement Advisory Services sold out of Cognition Therapeutics (CGTX) in Q1 2026, closing a stake of 10,000 shares — an estimated $14.1K sold.

Wealth Enhancement Advisory Services first reported a position in CGTX in Q4 2024 and held it in 5 quarters. The position peaked at $19.3K in Q3 2025. 75 funds tracked by Wall St. Rank hold CGTX as of Q1 2026.

  • Wealth Enhancement Advisory Services reported no remaining Cognition Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Wealth Enhancement Advisory Services sold 10,000 Cognition Therapeutics shares in Q1 2026, an estimated $14.1K.
  • Wealth Enhancement Advisory Services first reported a position in Cognition Therapeutics in Q4 2024 and held it in 5 quarters.
  • Wealth Enhancement Advisory Services's Cognition Therapeutics position peaked at $19.3K in Q3 2025.
  • 75 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q1 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q1 2026, filed 8 Apr 2026.